Can letrozole be repurposed for the treatment of visceral leishmaniasis?
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00756-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Juliana Martins Ribeiro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Hauptthemen laut MEDLINE: Leishmaniasis, Visceral, Leishmania infantum, Letrozole, Drug Repositioning. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Abstract (Originalsprache)
Visceral leishmaniasis, caused by Leishmania infantum in New World countries, is the most serious and potentially fatal form of leishmaniasis, if left untreated. There are currently no effective prophylactic measures, and therapeutic options are limited. Therefore, we investigated whether the aromatase inhibitor letrozole (LET), which is already used to treat breast cancer, has an antileishmanial activity and/or immunomodulatory potential and therefore may be used to treat L. infantum infection. LET was active against L. infantum promastigote and amastigote life cycle stages in an i n vitro infection model using human THP-1 cell-derived macrophages. In human peripheral blood leukocytes ex vivo , LET reduced the internalized forms of L. infantum by classical monocytes and activated neutrophils. Concomitantly, LET stimulated the production of IL-12/TNF-α and decreased the production of IL-10/TGF-β by peripheral blood phagocytes, while in T and B cells, it promoted the production of TNF-α/IFN-γ and decreased that of IL-10. In a murine infection model, LET significantly reduced the parasite load in the liver after just 5 days and in the spleen after 15 days. During in vivo treatment with LET, the production of TNF-α/IFN-γ also increased. In addition, the proportion of developing granulomas decreased and that of mature granulomas increased in the liver, while there was no significant change in organ architecture in the spleen. Based on these data, repositioning of LET may be promising for the treatment of visceral leishmaniasis in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
- Grupo de Genômica Funcional de Parasitos, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.
- Grupo Pesquisa Clínica e Políticas Públicas em Doenças Infecto-Parasitárias, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.
- Grupo Imunologia Celular e Molecular, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.
- Grupo Imunologia de Doenças Virais, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.
- Grupo Integrado de Pesquisa em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.
ORCID-Profile: Juliana Martins Ribeiro, Eliane de Morais Teixeira, Líndicy Leidicy Alves, Érica Alessandra Rocha Alves, Marcelo Antônio Pascoal-Xavier, Ana Maria Murta Santi, Edward Oliveira, Pedro Pires Goulart Guimarães, Andrea Teixeira-Carvalho, Silvane Maria Fonseca Murta, Vanessa Peruhype-Magalhães, Elaine Maria Souza-Fagundes
Förderung
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
- Alexander von Humboldt-Stiftung (AvH)
- Fundação Oswaldo Cruz (FIOCRUZ)
Zitieren
APA
Ribeiro, J. M., Teixeira, E. M., Alves, L. L., Alves, É. A. R., Pascoal-Xavier, M. A., Santi, A. M. M., Oliveira, E., Guimarães, P. P. G., Teixeira-Carvalho, A., Murta, S. M. F., Peruhype-Magalhães, V., & Souza-Fagundes, E. M. (2024). Can letrozole be repurposed for the treatment of visceral leishmaniasis?. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00756-24
Vancouver
Ribeiro JM, Teixeira EM, Alves LL, Alves ÉAR, Pascoal-Xavier MA, Santi AMM, et al. Can letrozole be repurposed for the treatment of visceral leishmaniasis?. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00756-24
BibTeX
@article{Ribeiro2024,
author = {Ribeiro, Juliana Martins and Teixeira, Eliane de Morais and Alves, Líndicy Leidicy and Alves, Érica Alessandra Rocha and Pascoal-Xavier, Marcelo Antônio and Santi, Ana Maria Murta and Oliveira, Edward and Guimarães, Pedro Pires Goulart and Teixeira-Carvalho, Andrea and Murta, Silvane Maria Fonseca and Peruhype-Magalhães, Vanessa and Souza-Fagundes, Elaine Maria},
title = {Can letrozole be repurposed for the treatment of visceral leishmaniasis?},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00756-24}
}
EUVIMED